Aller au contenu principal
Accès ouvert déclaré 2025 conference-abstract

Assessment of an oral corticosteroid withdrawal pathway for severe asthma patients receiving biologic therapies

0Citations signalées — pas une note de qualité
0Institutions déclarées
0Pays d’affiliation déclarés

Résumé fourni par la source

Background The optimal approach for weaning maintenance oral corticosteroids (mOCS) in severe asthma patients receiving biologics remains unclear. Previous studies assessed hypothalamic-pituitary-adrenal function at 5 mg daily prednisolone, a supraphysiological dose for many, necessitating further mOCS reduction for adrenal recovery. Objective We evaluated a protocol-driven nurse-led mOCS withdrawal pathway with clinical oversight for severe asthma patients receiving biologics. Methods Severe asthma patients receiving biologics who had reduced mOCS to 5 mg prednisolone daily and maintained good asthma control, entered the withdrawal pathway. Prednisolone was decreased to 4 mg daily for 6 weeks then 3 mg daily for 6 weeks, followed by 09.00 serum cortisol measurement. Patients with cortisol >25 nmol/L followed a 20-week weaning protocol. Serum cortisol was re-checked 12 weeks after stopping mOCS. Results Of 102 patients, 92 had cortisol >25 nmol/L on 3 mg prednisolone and continued weaning. Seventy-three (72%) successfully discontinued mOCS with median [IQR] cortisol increasing from 192 [88-299] nmol/L on 3 mg prednisolone to 314 [248-437] nmol/L 12 weeks after discontinuation (p<0.0001). Twenty-nine patients (28%) paused weaning due to adrenal insufficiency symptoms (n=22), worse asthma control (n=1), anxiety (n=2) and other reasons (n=4). The baseline cortisol in this group was 53 [25-166] nmol/L, and they are currently well receiving median 3.0 [3.0-3.9] mg prednisolone. Duration of prior OCS use was significantly shorter in the successfully weaned group compared to those who failed (p=0.003). No serious adverse events occurred. Conclusion Most clinically stable asthma patients receiving biologics successfully withdrew mOCS without requiring dynamic adrenal function testing.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
Assessment of an oral corticosteroid withdrawal pathway for severe asthma patients receiving biologic therapies
Date Crossref
19/02/2025
Éditeur
Bioscientifica
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude et ne compte pas comme une seconde source scientifique indépendante.

Sujets associés

Pharmaceutical studies and practicesAsthma and respiratory diseasesInhalation and Respiratory Drug Delivery

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, ROR et la Banque mondiale, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune donnée externe enregistrée en base. Sources et limites.